Tempest Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-84.6M | $-82.3M | $-73.2M | $-49.5M | $-29.0M | $-13.5M |
| Depreciation & Amortization | $1.7M | $2.2M | $1.3M | $450.0K | $231.0K | $93.0K |
| Depreciation | $28.0K | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $6.9M | $9.2M | $19.3M | $12.4M | $5.1M | $1.4M |
| Net Cash from Operating Activities | $-20.3M | $-61.7M | $-50.3M | $-30.6M | $-18.1M | $-11.2M |
| Investing Activities | ||||||
| Capital Expenditures | $4.0K | $2.6M | $5.2M | $2.8M | $719.0K | $849.0K |
| Business Acquisitions | $-462.0K | — | — | — | — | — |
| Net Cash from Investing Activities | $458.0K | $8.3M | $-38.3M | $-32.8M | $-11.0M | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-4.5M | $54.1M | $125.4M | $51.7M | $32.4M | — |
| Net Change in Cash | $-24.3M | — | — | — | — | — |
| Free Cash Flow | $-20.3M | $-64.3M | $-55.5M | $-33.4M | $-18.8M | $-12.0M |